Management of MSI-H/dMMR Metastatic Colorectal Cancer

Management of MSI-H/dMMR Metastatic Colorectal Cancer

Navigating First-Line Therapy Choices in Advanced Melanoma: Evidence, Patient Factors, and Shared Decision-Making
icon-objectives

Learning Objectives

  1. Explore recent advances in immunotherapy-based treatment options for MSI-H/dMMR metastatic colorectal cancer.
  2. Apply data from the CheckMate-8HW trial to guide the development of individualized treatment plans.
  3. Examine best practices in patient management to optimize clinical outcomes.
  4. Identify, recognize, and manage immune-mediated adverse events effectively.
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Speakers

Dr. Eric Chen

Dr. Mustapha Tehfe

Studies / Trials Discussed

Abstract #3501 – Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.

This program has been made possible through unrestricted support from BMS

Studies/trials discussed:

Abstract #3501 – Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.
Tagged